Absence of gene mutations in KIT-positive thymic epithelial tumors

Lung Cancer

Volumn 62, Issue 3, 2008, Pages 321-325

  Tsuchida, Masanori ^a   Umezu, Hajime ^b   Hashimoto, Takehisa ^a   Shinohara, Hirohiko ^a   Koike, Terumoto ^a   Hosaka, Yasuko ^a   Eimoto, Tadaaki ^c   Hayashi, Jun ich ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Immunohistochemical staining; KIT expression; Mutation analysis; Thymic cancer

Indexed keywords

CD5 ANTIGEN; STEM CELL FACTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; THYMOMA; THYMUS CANCER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; THYMOMA; THYMUS NEOPLASMS; YOUNG ADULT;

EID: 56949103171     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.03.035     Document Type: Article

References (23)

1. Chung D.A. Thymic carcinoma-analysis of nineteen clinicopathological studies. Thorac Cardiovasc Surg 48 (2000) 114-119
2. Yarden Y., Kuang W.J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J., et al. Human-proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6 (1987) 3341-3351
3. Vandenbark G.R., deCastro C.M., Taylor H., Dew-Knight S., and Kaufman R.E. Cloning and structural analysis of the human c-kit gene. Oncogene 7 (1992) 1259-1266
4. Arber D.A., Tamayo R., and Weiss L.M. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 29 (1998) 498-504
5. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., et al. Gain of function mutation of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
6. Kimura A., Nakata Y., Katoh O., and Hyodo H. c-kit point mutation in patients with myeloproliferative disorders. Leuk Lymphoma 25 (1997) 281-287
7. Pache M., Glatz K., Bösch D., Dirnhofer S., Mirlacher M., Simon R., et al. Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 443 (2003) 741-744
8. Kemmer K., Corless C.L., Fletcher J.A., McGreevev L., Haley A., Griffith D., et al. KIT mutations are common in testicular seminomas. Am J Pathol 164 (2004) 305-313
9. Henley J.D., Cummings Sr. O.W., and Loehrer P.J. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130 (2004) 222-224
10. Nakagawa K., Matsuno Y., Kunitoh H., Maeshima A., Asamura H., and Tsuchiya R. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 128 (2005) 140-144
11. Pan C.C., Chen P.C., and Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202 (2004) 375-381
12. Taniguchi M., Nishida T., Hirota S., Isozaki K., Ito T., Nomura T., et al. Effect of c-kit mutations on prognosis of gastrointestinal stromal tumors. Cancer Res 59 (1999) 4297-4300
13. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to Imatinib. New Engl J Med 350 (2004) 2625-2626
14. In: Travis W.D., Brambilla E., Muller-Hermelink, and Harris C.C. (Eds). Pathology and genetics of tumors of the lung, pleura, thymus and heart World Health Organization classification of tumors. (2004), IARC, Lyon, France
15. Masaoka A., Monden Y., Nakahara K., and Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 (1981) 2485-2492
16. Saito M., Sakurai S., Motegi A., Saito K., Sano T., and Nakajima T. Comparative study using rabbit-derived polyclonal, mouse-derived monoclonal, and rabbit-derived monoclonal antibodies for KIT immunostaining in GIST and other tumors. Pathol Int 57 (2007) 200-204
17. Hongyo T., Buzard G.S., Calvert R.J., and Weghorst C.M. 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucl Acids Res 21 (1993) 3637-3642
18. Wakai T., Kanda T., Hirota S., Ohashi A., Shuri Y., and Hatakeyama K. Late resistance to Imatinib therapy in a metastatic gastrointestinal stromal tumor is associated with a second KIT mutation. Br J Cancer 90 (2004) 2059-2061
19. Yaren A., Oztop I., Kargi A., Ulukus C., Onen A., Sanli A., et al. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. J Clin Prac 60 (2006) 675-682
20. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and Imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
21. Meister M., Schirmacher P., Dienemann H., Mechtersheimer G., Schnabel P.A., Kem M.A., et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 248 (2007) 186-191
22. Farina G., Garassino M.C., Gambacorta M., La Verde N., Gherardi G., and Scanni A. Response of thymoma to cetuximab. Lancet Oncol 8 (2007) 449-450
23. Palmieri G., Marino M., Salvatore M., Budillon A., Meo G., Caraqlia M., et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 12 (2007) 757-761